American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm—2023 update

Samson, Susan L.; Vellanki, Priyathama; Blonde, Lawrence; Christofides, Elena A.; Galindo, Rodolfo J.; Hirsch, Irl B.; Isaacs, Scott D.; Izuora, Kenneth E.; Low Wang, Cecilia C.; Twining, Christine L.; Umpierrez, Guillermo E.; Valencia, Willy Marcos

doi:10.1016/j.eprac.2023.02.001

Cited by 375Diabetes Treatment and ManagementDiabetes Management and ResearchDiabetes, Cardiovascular Risks, and Lipoproteins

American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm—2023 update

Samson, Susan L., Vellanki, Priyathama, Blonde, Lawrence, Christofides, Elena A., Galindo, Rodolfo J., Hirsch, Irl B., Isaacs, Scott D., Izuora, Kenneth E. +4 more·2023·Endocrine Practice

DOI 10.1016/j.eprac.2023.02.001

Open this paper in CoChat — free account

Abstract

OBJECTIVE This consensus statement provides (1) visual guidance in concise graphic algorithms to assist with clinical decision-making of health care professionals in the management of persons with type 2 diabetes mellitus to improve patient care and (2) a summary of details to support the visual guidance found in each algorithm. METHODS The American Association of Clinical Endocrinology (AACE) selected a task force of medical experts who updated the 2020 AACE Comprehensive Type 2 Diabetes Management Algorithm based on the 2022 AACE Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan and consensus of task force authors. RESULTS This algorithm for management of persons with type 2 diabetes includes 11 distinct sections: (1) Principles for the Management of Type 2 Diabetes; (2) Complications-Centric Model for the Care of Persons with Overweight/Obesity; (3) Prediabetes Algorithm; (4) Atherosclerotic Cardiovascular Disease Risk Reduction Algorithm: Dyslipidemia; (5) Atherosclerotic Cardiovascular Disease Risk Reduction Algorithm: Hypertension; (6) Complications-Centric Algorithm for Glycemic Control; (7) Glucose-Centric Algorithm for Glycemic Control; (8) Algorithm for Adding/Intensifying Insulin; (9) Profiles of Antihyperglycemic Medications; (10) Profiles of Weight-Loss Medications (new); and (11) Vaccine Recommendations for Persons with Diabetes Mellitus (new), which summarizes recommendations from the Advisory Committee on Immunization Practices of the U.S. Centers for Disease Control and Prevention. CONCLUSIONS Aligning with the 2022 AACE diabetes guideline update, this 2023 diabetes algorithm update emphasizes lifestyle modification and treatment of overweight/obesity as key pillars in the management of prediabetes and diabetes mellitus and highlights the importance of appropriate management of atherosclerotic risk factors of dyslipidemia and hypertension. One notable new theme is an emphasis on a complication-centric approach, beyond glucose levels, to frame decisions regarding first-line pharmacologic choices for the treatment of persons with diabetes. The algorithm also includes access/cost of medications as factors related to health equity to consider in clinical decision-making.

Integrity signals

Registry

Crossref · 10.1016/j.eprac.2023.02.001

Cites

177 of 177 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Recent guidelines call for continuous glucose monitoring (CGM) use for all who require insulin, regardless of diabetes type.
“While recent guidelines call for continuous glucose monitoring (CGM) use for all who require insulin, regardless of diabetes type (7), there is also evidence that patients may not know how to interpret what to do with the CGM data (6, 8, 9).”
From Observed Glycemic and Psychosocial Benefits in the Prospective Bigfoot Unity Real World Study: A 6-Month Analysis (2025) · cites this paper as [7]

The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910 · see citing works
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032 · see citing works
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · see citing works
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.
(2002) · Circulation · doi:10.1161/circ.106.25.3143 · Cited by 14,092 · see citing works
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315 · see citing works
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830 · see citing works
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397 · see citing works
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
(1998) · BMJ · doi:10.1136/bmj.317.7160.703 · Cited by 6,683 · see citing works
Effects on Blood Pressure of Reduced Dietary Sodium and the Dietary Approaches to Stop Hypertension (DASH) Diet
Sacks, F. M., Svetkey, L. P., Vollmer, W. M., Appel, L. J., Bray, G. A., Harsha, D., Obarzanek, E., Conlin, P. R., Miller, E. R., Simons-Morton, D. G., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200101043440101 · Cited by 5,638 · see citing works
Cardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206 · see citing works
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · see citing works
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men
Lakka, H.-M. (2002) · JAMA · doi:10.1001/jama.288.21.2709 · Cited by 5,033 · see citing works
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762 · see citing works
The WHO-5 well-being index: A systematic review of the literature
Topp, C. W., Østergaard, S. D., Søndergaard, S., & Bech, P. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000376585 · Cited by 4,708 · see citing works
Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study
Pan, X.-R., Li, G.-W., Hu, Y.-H., Wang, J.-X., Yang, W.-Y., An, Z.-X., Hu, Z.-X., Juan-Lin, Xiao, J.-Z., Cao, H.-B., et al. (1997) · Diabetes Care · doi:10.2337/diacare.20.4.537 · Cited by 4,320 · see citing works
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845 · see citing works
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · see citing works
Telmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502 · see citing works
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470 · see citing works
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317 · see citing works
Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935 · see citing works
Empagliflozin in Patients with Chronic Kidney Disease
The EMPA-KIDNEY Collaborative Group (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2204233 · Cited by 2,754 · see citing works
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., & Laakso, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08905-5 · Cited by 2,543 · see citing works
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436 · see citing works
STOP Questionnaire: A Tool to Screen Patients for Obstructive Sleep Apnea
Chung, F., Yegneswaran, B., Liao, P., Chung, S. A., Vairavanathan, S., Islam, S., Khajehdehi, A., & Shapiro, C. M. (2008) · Anesthesiology · doi:10.1097/aln.0b013e31816d83e4 · Cited by 2,355 · see citing works
Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study
Adler, A. I. (2000) · BMJ · doi:10.1136/bmj.321.7258.412 · Cited by 2,133 · see citing works
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104 · see citing works
Exercise and Type 2 Diabetes
Colberg, S. R., Sigal, R. J., Fernhall, B., Regensteiner, J. G., Blissmer, B. J., Rubin, R. R., Chasan-Taber, L., Albright, A. L., & Braun, B. (2010) · Diabetes Care · doi:10.2337/dc10-9990 · Cited by 1,955 · see citing works
Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes
Wing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828 · see citing works
Cardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814 · see citing works
Exercise Training for Blood Pressure: A Systematic Review and Meta‐analysis
Cornelissen, V. A., & Smart, N. A. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.112.004473 · Cited by 1,683 · see citing works
Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients With Impaired Glucose Tolerance: The STOP-NIDDM Trial
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., Laakso, M., & for The STOP-NIDDM Trial Research Group (2003) · JAMA · doi:10.1001/jama.290.4.486 · Cited by 1,624 · see citing works
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
Sattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599 · see citing works
Untitled work
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479 · see citing works
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444 · see citing works
Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial
Ismail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428 · see citing works
Influence of Weight Reduction on Blood Pressure: A Meta-Analysis of Randomized Controlled Trials
Neter, J. E., Stam, B. E., Kok, F. J., Grobbee, D. E., & Geleijnse, J. M. (2003) · Hypertension · doi:10.1161/01.hyp.0000094221.86888.ae · Cited by 1,391 · see citing works
Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy: A Meta-analysis
Preiss, D. (2011) · JAMA · doi:10.1001/jama.2011.860 · Cited by 1,390 · see citing works
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
Agarwal, R., Filippatos, G., Pitt, B., Anker, S. D., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Gebel, M., Ruilope, L. M., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab777 · Cited by 1,317 · see citing works
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis
McGuire, D. K., Shih, W. J., Cosentino, F., Charbonnel, B., Cherney, D. Z. I., Dagogo-Jack, S., Pratley, R., Greenberg, M., Wang, S., Huyck, S., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.4511 · Cited by 1,235 · see citing works
Combined angiotensin inhibition for the treatment of diabetic nephropathy
Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., Leehey, D. J., McCullough, P. A., O'Connor, T., Palevsky, P. M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303154 · Cited by 1,169 · see citing works
2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk
Eckel, R. H., Jakicic, J. M., Ard, J. D., de Jesus, J. M., Houston Miller, N., Hubbard, V. S., Lee, I.-M., Lichtenstein, A. H., Loria, C. M., Millen, B. E., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.003 · Cited by 1,160 · see citing works
Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association
Carey, R. M., Calhoun, D. A., Bakris, G. L., Brook, R. D., Daugherty, S. L., Dennison-Himmelfarb, C. R., Egan, B. M., Flack, J. M., Gidding, S. S., Judd, E., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000084 · Cited by 1,153 · see citing works
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114 · see citing works
Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: A prospective study
Norhammar, A., Tenerz, Å., Nilsson, G., Hamsten, A., Efendíc, S., Rydén, L., & Malmberg, K. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09089-x · Cited by 1,112 · see citing works
American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease
Jellinger, P. S., Handelsman, Y., Rosenblit, P. D., Bloomgarden, Z. T., Fonseca, V. A., Garber, A. J., Grunberger, G., Guerin, C. K., Bell, D. S. H., Mechanick, J. I., et al. (2017) · Endocrine Practice · doi:10.4158/ep171764.appgl · Cited by 1,094 · see citing works
Association of Hemoglobin A <sub>1c</sub> with Cardiovascular Disease and Mortality in Adults: The European Prospective Investigation into Cancer in Norfolk
Khaw, K.-T., Wareham, N., Bingham, S., Luben, R., Welch, A., & Day, N. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-6-200409210-00006 · Cited by 974 · see citing works
Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control
Rodbard, H. W., Jellinger, P. S., Davidson, J. A., Einhorn, D., Garber, A. J., Grunberger, G., Handelsman, Y., Horton, E. S., Lebovitz, H., Levy, P., et al. (2009) · Endocrine Practice · doi:10.4158/ep.15.6.540 · Cited by 942 · see citing works
Metabolic Syndrome and Development of Diabetes Mellitus: Application and Validation of Recently Suggested Definitions of the Metabolic Syndrome in a Prospective Cohort Study
Laaksonen, D. E. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf145 · Cited by 916 · see citing works
Diabetic dyslipidaemia: from basic research to clinical practice*
Taskinen, M.-R. (2003) · Diabetologia · doi:10.1007/s00125-003-1111-y · Cited by 888 · see citing works
Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm – 2016 EXECUTIVE SUMMARY
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S. E., DeFronzo, R. A., EINHORN, D. F., Fonseca, V. A., et al. (2016) · Endocrine Practice · doi:10.4158/ep151126.cs · Cited by 874 · see citing works
Self-citation
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850 · see citing works
C-Reactive Protein and Parental History Improve Global Cardiovascular Risk Prediction: The Reynolds Risk Score for Men
Ridker, P. M., Paynter, N. P., Rifai, N., Gaziano, J. M., & Cook, N. R. (2008) · Circulation · doi:10.1161/circulationaha.108.814251 · Cited by 841 · see citing works
Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association
Newman, C. B., Preiss, D., Tobert, J. A., Jacobson, T. A., Page, R. L., II, Goldstein, L. B., Chin, C. C., Tannock, L. R., Miller, M. J., Raghuveer, G., et al. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atv.0000000000000073 · Cited by 760 · see citing works
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
Zannad, F., Cannon, C. P., Cushman, W. C., Bakris, G. L., Menon, V., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., Wilson, C., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62225-x · Cited by 757 · see citing works
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials
Viney, N. J., van Capelleveen, J. C., Geary, R. S., Xia, S., Tami, J. A., Yu, R. Z., Marcovina, S. M., Hughes, S. G., Graham, M. J., Crooke, R. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31009-1 · Cited by 754 · see citing works
Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance
DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Henry, R. R., Hodis, H. N., Kitabchi, A. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010949 · Cited by 752 · see citing works
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk
Das Pradhan, A., Glynn, R. J., Fruchart, J.-C., MacFadyen, J. G., Zaharris, E. S., Everett, B. M., Campbell, S. E., Oshima, R., Amarenco, P., Blom, D. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2210645 · Cited by 749 · see citing works
Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring
Bergenstal, R. M., Beck, R. W., Close, K. L., Grunberger, G., Sacks, D. B., Kowalski, A., Brown, A. S., Heinemann, L., Aleppo, G., Ryan, D. B., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1581 · Cited by 684 · see citing works
A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk
Sniderman, A. D., Williams, K., Contois, J. H., Monroe, H. M., McQueen, M. J., de Graaf, J., & Furberg, C. D. (2011) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.110.959247 · Cited by 659 · see citing works
Untitled work
Colberg (2010) · doi:10.2337/dc10-1548 · Cited by 656 · see citing works
Prevention of Diabetes With Mediterranean Diets: A Subgroup Analysis of a Randomized Trial
Salas-Salvadó, J., Bulló, M., Estruch, R., Ros, E., Covas, M.-I., Ibarrola-Jurado, N., Corella, D., Arós, F., Gómez-Gracia, E., Ruiz-Gutiérrez, V., et al. (2014) · Annals of Internal Medicine · doi:10.7326/m13-1725 · Cited by 650 · see citing works
Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial
Haak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0223-6 · Cited by 623 · see citing works
Physical Activity in the Prevention of Type 2 Diabetes
Laaksonen, D. E., Lindström, J., Lakka, T. A., Eriksson, J. G., Niskanen, L., Wikström, K., Aunola, S., Keinänen-Kiukaanniemi, S., Laakso, M., Valle, T. T., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.1.158 · Cited by 614 · see citing works
Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary
Garber, A. J., Handelsman, Y., Grunberger, G., Einhorn, D., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bush, M. A., DeFronzo, R. A., Garber, J. R., et al. (2020) · Endocrine Practice · doi:10.4158/cs-2019-0472 · Cited by 598 · see citing works
Self-citation
Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review
Sniderman, A. D., Thanassoulis, G., Glavinovic, T., Navar, A. M., Pencina, M., Catapano, A., & Ference, B. A. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.3780 · Cited by 593 · see citing works
Diabetes Mellitus–Related All‐Cause and Cardiovascular Mortality in a National Cohort of Adults
Raghavan, S., Vassy, J. L., Ho, Y.-L. A., Song, R. J., GAGNON, D. R., Cho, K., Wilson, P. W. F., & Phillips, L. S. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011295 · Cited by 559 · see citing works
Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome
Scott, R., O'Brien, R., Fulcher, G., Pardy, C., d'Emden, M., Tse, D., Taskinen, M.-R., Ehnholm, C., Keech, A., & on behalf of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-1543 · Cited by 551 · see citing works
Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial
Martens, T., Beck, R. W., Bailey, R., Ruedy, K. J., Calhoun, P., Peters, A. L., Pop-Busui, R., Philis-Tsimikas, A., Bao, S., Umpierrez, G., et al. (2021) · JAMA · doi:10.1001/jama.2021.7444 · Cited by 543 · see citing works
Self-citation
Effects of Dietary Patterns on Blood Pressure: Subgroup Analysis of the Dietary Approaches to Stop Hypertension (DASH) Randomized Clinical Trial
Svetkey, L. P. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.3.285 · Cited by 527 · see citing works
Lipoprotein Management in Patients With Cardiometabolic Risk
Brunzell, J. D., Davidson, M. H., Furberg, C. D., Goldberg, R. B., Howard, B. V., Stein, J. H., & Witztum, J. L. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.02.034 · Cited by 523 · see citing works
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507 · see citing works
Self-citation
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S. E., DeFronzo, R. A., EINHORN, D. F., Fonseca, V. A., et al. (2018) · Endocrine Practice · doi:10.4158/cs-2017-0153 · Cited by 499 · see citing works
Self-citation
The relationships between time in range, hyperglycemia metrics, and HbA1c
Beck, R. W., Bergenstal, R. M., Cheng, P., Kollman, C., Carlson, A. L., Johnson, M. L., & Rodbard, D. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818822496 · Cited by 479 · see citing works
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
Das, S. R., Everett, B. M., Birtcher, K. K., Brown, J. M., Januzzi, J. L., Kalyani, R. R., Kosiborod, M., Magwire, M., Morris, P. B., Neumiller, J. J., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.037 · Cited by 466 · see citing works
The relationship of hemoglobin A1C to time-in-range in patients with diabetes
Vigersky, R. A., & McMahon, C. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0310 · Cited by 464 · see citing works
Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis
Baker, W. L., Smyth, L. R., Riche, D. M., Bourret, E. M., Chamberlin, K. W., & White, W. B. (2014) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2014.01.007 · Cited by 452 · see citing works
Patient reminder and recall interventions to improve immunization rates
Jacobson Vann, J. C., Jacobson, R. M., Coyne-Beasley, T., Asafu-Adjei, J. K., & Szilagyi, P. G. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003941.pub3 · Cited by 396 · see citing works
Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis
Palmer, S. C., Mavridis, D., Navarese, E., Craig, J. C., Tonelli, M., Salanti, G., Wiebe, N., Ruospo, M., Wheeler, D. C., & Strippoli, G. F. M. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62459-4 · Cited by 395 · see citing works
Aace Comprehensive Diabetes Management Algorithm 2013
Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S. E., Davidson, M., EINHORN, D. F., Garvey, W. T., Grunberger, G., et al. (2013) · Endocrine Practice · doi:10.4158/endp.19.2.a38267720403k242 · Cited by 393 · see citing works
Self-citation
Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review
Khunti, K. K., Gomes, M. B., Pocock, S., Shestakova, M. V., Pintat, S., Fenici, P., Hammar, N., & Medina, J. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13088 · Cited by 376 · see citing works
Barriers to Adult Immunization
Johnson, D. R., Nichol, K. L., & Lipczynski, K. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.05.005 · Cited by 371 · see citing works
Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): A 5-year, multicentre, randomised, double-blind trial
Matthews, D. R., Paldánius, P. M., Proot, P., Chiang, Y., Stumvoll, M., & Del Prato, S. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32131-2 · Cited by 364 · see citing works
Bioenterics intragastric balloon: the Italian experience with 2,515 patients
Genco, A., Bruni, T., Doldi, S. B., Forestieri, P., Marino, M., Busetto, L., Giardiello, C., Angrisani, L., Pecchioli, L., Stornelli, P., et al. (2005) · Obesity Surgery · doi:10.1381/0960892055002202 · Cited by 361 · see citing works
Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients
Johannesen, C. D. L., Mortensen, M. B., Langsted, A., & Nordestgaard, B. G. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.01.027 · Cited by 359 · see citing works
Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients
Mazidi, M., Rezaie, P., Gao, H., & Kengne, A. P. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004007 · Cited by 347 · see citing works
Surveillance of Vaccination Coverage Among Adult Populations —United States, 2018
Lu, P.-J., Hung, M.-C., Srivastav, A., Grohskopf, L. A., Kobayashi, M., Harris, A. M., Dooling, K. L., Markowitz, L. E., Rodríguez-Lainz, A., & Williams, W. W. (2021) · MMWR Surveillance Summaries · doi:10.15585/mmwr.ss7003a1 · Cited by 347 · see citing works
Renal Outcomes in High-Risk Hypertensive Patients Treated With an Angiotensin-Converting Enzyme Inhibitor or a Calcium Channel Blocker vs a Diuretic: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Rahman, M. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.8.936 · Cited by 340 · see citing works
Hypothesis: β-Adrenergic Receptor Blockers and Weight Gain
Sharma, A. M., Pischon, T., Hardt, S., Kunz, I., & Luft, F. C. (2001) · Hypertension · doi:10.1161/01.hyp.37.2.250 · Cited by 339 · see citing works
Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial
Holman, R. R., Coleman, R. L., Chan, J. C. N., Chiasson, J.-L., Feng, H., Ge, J., Gerstein, H. C., Gray, R., Huo, Y., Lang, Z., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30309-1 · Cited by 323 · see citing works
Self-citation
Adiposity-Based Chronic Disease as a new Diagnostic Term: The American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement
Mechanick, J. I., Hurley, D. L., & Garvey, W. T. (2017) · Endocrine Practice · doi:10.4158/ep161688.ps · Cited by 320 · see citing works
Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis
Sun, F., Wu, S., Guo, S., Yu, K., Yang, Z., Li, L., Zhang, Y., Quan, X., Ji, L., & Zhan, S. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.07.015 · Cited by 304 · see citing works
Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2019 executive summary.
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2019) · Endocrine Practice · doi:10.4158/cs-2018-0535 · Cited by 297 · see citing works
Self-citation
American Association of Clinical Endocrinology clinical practice guideline: the use of advanced technology in the management of persons with diabetes mellitus
Grunberger, G., Sherr, J., Allende, M., Blevins, T., Bode, B., Handelsman, Y., Hellman, R., Lajara, R., Roberts, V. L., Rodbard, D., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.04.008 · Cited by 288 · see citing works
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function
Zannad, F. M., Ferreira, J. P., Pocock, S., Zeller, C., Anker, S. D., Butler, J., Filippatos, G. S., Hauske, S. J., Brueckmann, M., Pfarr, E., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.051685 · Cited by 281 · see citing works
The REDUCE pivotal trial: A prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity
Ponce, J., Woodman, G., Swain, J., Wilson, E., English, W., Ikramuddin, S., Bour, E., Edmundowicz, S., Snyder, B., Soto, F., et al. (2015) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2014.12.006 · Cited by 279 · see citing works
Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis
Kramer, C. K., Zinman, B., & Retnakaran, R. R. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70006-8 · Cited by 264 · see citing works
COVID-19 Severity Is Tripled in the Diabetes Community: A Prospective Analysis of the Pandemic’s Impact in Type 1 and Type 2 Diabetes
Gregory, J. M., Slaughter, J. C., Duffus, S. H., Smith, T. J., LeStourgeon, L. M., Jaser, S. S., McCoy, A. B., Luther, J. M., Giovannetti, E. R., BOEDER, S. C., et al. (2020) · Diabetes Care · doi:10.2337/dc20-2260 · Cited by 256 · see citing works
Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm - 2020 executive summary
Handelsman, Y., Jellinger, P. S., Guerin, C. K., Bloomgarden, Z. T., Brinton, E. A., Budoff, M. J., Davidson, M. H., Einhorn, D., Fazio, S., Fonseca, V. A., et al. (2020) · Endocrine Practice · doi:10.4158/cs-2020-0490 · Cited by 248 · see citing works
Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis
Lee, M., Saver, J. L., Towfighi, A., Chow, J., & Ovbiagele, B. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.04.020 · Cited by 240 · see citing works
Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk
Sniderman, A. D., St-Pierre, A. C., Cantin, B., Dagenais, G. R., Després, J.-P., & Lamarche, B. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00262-5 · Cited by 224 · see citing works
Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release
Garvey, W. T., Ryan, D. H., Henry, R., Bohannon, N. J. V., Toplak, H., Schwiers, M., Troupin, B., & Day, W. W. (2014) · Diabetes Care · doi:10.2337/dc13-1518 · Cited by 215 · see citing works
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
Heerspink, H. J. L., Jongs, N., Chertow, G. M., Langkilde, A. M., McMurray, J. J. V., Correa‐Rotter, R., Rossing, P. R., Sjöström, C. D., Stefánsson, B. V., Toto, R. D., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00242-4 · Cited by 209 · see citing works
Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis
Bruckert, E., Labreuche, J., Deplanque, D., Touboul, P.-J., & Amarenco, P. (2011) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318202709f · Cited by 192 · see citing works
A Mediterranean diet lowers blood pressure and improves endothelial function: results from the MedLey randomized intervention trial
Davis, C. R., Hodgson, J. M., Woodman, R., Bryan, J., Wilson, C., & Murphy, K. J. (2017) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.116.146803 · Cited by 191 · see citing works
Association of real-time continuous glucose monitoring with glycemic control and acute metabolic events among patients with insulin-treated diabetes
Karter, A. J., Parker, M. M., Moffet, H. H., Gilliam, L. K., & Dlott, R. (2021) · JAMA · doi:10.1001/jama.2021.6530 · Cited by 191 · see citing works
Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants
Wang, N., Fulcher, J., Abeysuriya, N., Park, L., Kumar, S., Di Tanna, G. L., Wilcox, I., Keech, A., Rodgers, A., & Lal, S. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30388-2 · Cited by 187 · see citing works
A randomized, double-blind, placebo-controlled study of gelesis100: A novel nonsystemic oral hydrogel for weight loss
Greenway, F. L., Aronne, L. J., Raben, A., Astrup, A., Apovian, C. M., Hill, J. O., Kaplan, L. M., Fujioka, K., Matejkova, E., Svacina, S., et al. (2019) · Obesity · doi:10.1002/oby.22347 · Cited by 179 · see citing works
Effects of Coenzyme Q10 on Statin‐Induced Myopathy: An Updated Meta‐Analysis of Randomized Controlled Trials
Qu, H., Guo, M., Chai, H., Wang, W., Gao, Z., & Shi, D. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009835 · Cited by 178 · see citing works
Use of influenza and pneumococcal vaccines in people with diabetes
Smith, S. A., & Poland, G. A. (2000) · Diabetes Care · doi:10.2337/diacare.23.1.95 · Cited by 155 · see citing works
Benefits and harms of intensive glycemic control in patients with type 2 diabetes
Rodriguez-Gutierrez, R., Gonzalez-Gonzalez, J. G., Zuñiga-Hernandez, J. A., & McCoy, R. G. (2019) · BMJ · doi:10.1136/bmj.l5887 · Cited by 152 · see citing works
Pioglitazone for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis
Lee, M., Saver, J. L., Liao, H.-W., Lin, C.-H., & Ovbiagele, B. (2017) · Stroke · doi:10.1161/strokeaha.116.013977 · Cited by 147 · see citing works
Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial
Mann, J. F. E., Fonseca, V., Mosenzon, O., Raz, I., Goldman, B., Idorn, T., von Scholten, B. J., Poulter, N. R., & The LEADER Publication Committee on behalf of the LEADER Trial Investigators (2018) · Circulation · doi:10.1161/circulationaha.118.036418 · Cited by 147 · see citing works
Initiate Insulin by Aggressive Titration and Education (INITIATE)
Yki-Järvinen, H., Juurinen, L., Alvarsson, M., Bystedt, T., Caldwell, I., Davies, M., Lahdenperä, S., Nijpels, G., & Vähätalo, M. (2007) · Diabetes Care · doi:10.2337/dc06-1357 · Cited by 139 · see citing works
Efficacy of interventions that include diet, aerobic and resistance training components for type 2 diabetes prevention: A systematic review with meta-analysis
Aguiar, E. J., Morgan, P. J., Collins, C. E., Plotnikoff, R. C., & Callister, R. (2014) · International Journal of Behavioral Nutrition and Physical Activity · doi:10.1186/1479-5868-11-2 · Cited by 135 · see citing works
Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single‐dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs
Lankisch, M., Ferlinz, K., Leahy, J. L., Scherbaum, W. A., & Orals Plus Apidra and LANTUS (OPAL) study group (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00967.x · Cited by 133 · see citing works
Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study
Rickels, M. R., Ruedy, K. J., Foster, N. C., Piché, C. A., Dulude, H., Sherr, J. L., Tamborlane, W. V., Bethin, K. E., DiMeglio, L. A., Wadwa, R. P., et al. (2015) · Diabetes Care · doi:10.2337/dc15-1498 · Cited by 129 · see citing works
MANAGEMENT OF ENDOCRINE DISEASE: Diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited
Williams, T. A., & Reincke, M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0990 · Cited by 127 · see citing works
Weight loss and improved quality of life with a nonsurgical endoscopic treatment for obesity: clinical results from a 3- and 6-month study
Marinos, G., Eliades, C., Raman Muthusamy, V., & Greenway, F. (2014) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2014.03.005 · Cited by 123 · see citing works
U.S. Physicians’ Perspective of Adult Vaccine Delivery
Hurley, L. P., Bridges, C. B., Harpaz, R., Allison, M. A., O’Leary, S. T., Crane, L. A., Brtnikova, M., Stokley, S. K., Beaty, B. L., Jimenez-Zambrano, A. M., et al. (2014) · Annals of Internal Medicine · doi:10.7326/m13-2332 · Cited by 123 · see citing works
Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes
Sherr, J. L., Ruedy, K. J., Foster, N. C., Piché, C. A., Dulude, H., Rickels, M. R., Tamborlane, W. V., Bethin, K. E., DiMeglio, L. A., Fox, L. A., et al. (2016) · Diabetes Care · doi:10.2337/dc15-1606 · Cited by 122 · see citing works
Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study
Halcox, J. P., Banegas, J. R., Roy, C., Dallongeville, J., De Backer, G., Guallar, E., Perk, J., Hajage, D., Henriksson, K. M., & Borghi, C. (2017) · BMC Cardiovascular Disorders · doi:10.1186/s12872-017-0591-5 · Cited by 122 · see citing works
Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease
Zhou, Z., Jardine, M., Li, Q., Neuen, B. L., Cannon, C. P., de Zeeuw, D., Edwards, R., Levin, A., Mahaffey, K. W., Perkovic, V., et al. (2021) · Stroke · doi:10.1161/strokeaha.120.031623 · Cited by 118 · see citing works
Pharmacokinetic and pharmacodynamic characteristics of dasiglucagon, a novel soluble and stable glucagon analog
Hövelmann, U., Bysted, B. V., Mouritzen, U., Macchi, F., Lamers, D., Kronshage, B., Møller, D. V., & Heise, T. (2018) · Diabetes Care · doi:10.2337/dc17-1402 · Cited by 115 · see citing works
Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis.
Tsai, W.-H., Chuang, S.-M., Liu, S.-C., Lee, C.-C., Chien, M.-N., Leung, C.-H., Liu, S.-J., & Shih, H.-M. (2021) · Scientific Reports · doi:10.1038/s41598-021-94945-4 · Cited by 113 · see citing works
Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome
Giraldez, R. R., Clare, R. M., Lopes, R. D., Dalby, A. J., Prabhakaran, D., Brogan, G. X., Giugliano, R. P., James, S. K., Tanguay, J.-F., Pollack, C. V., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.01.005 · Cited by 111 · see citing works
Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial
Spence, J. D., Viscoli, C. M., Inzucchi, S. E., Dearborn-Tomazos, J., Ford, G. A., Gorman, M., Furie, K. L., Lovejoy, A. M., Young, L. H., Kernan, W. N., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.0079 · Cited by 109 · see citing works
Use of beta‐blockers in obesity hypertension: potential role of weight gain
Pischon, T., & Sharma, A. M. (2001) · Obesity Reviews · doi:10.1046/j.1467-789x.2001.00044.x · Cited by 103 · see citing works
Effects of initiation and titration of a single pre‐prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6‐month ‘proof‐of‐concept' study
Owens, D. R., Luzio, S. D., Sert-Langeron, C., & Riddle, M. C. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01459.x · Cited by 99 · see citing works
Trends in blood pressure control and treatment among type 2 diabetes with comorbid hypertension in the United States: 1988-2004
Suh, D.-C., Kim, C.-M., Choi, I.-S., Plauschinat, C. A., & Barone, J. A. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e32832d4aee · Cited by 99 · see citing works
Impacts of Prediabetes Mellitus Alone or Plus Hypertension on the Coronary Severity and Cardiovascular Outcomes
Liu, H., Cao, Y., Li, S., Guo, Y., Zhu, C., Wu, N., Gao, Y., Dong, Q., Zhao, X., Zhang, Y., et al. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.11063 · Cited by 99 · see citing works
Strategies for overcoming therapeutic inertia in type 2 diabetes: A systematic review and meta-analysis
Powell, R. E., Zaccardi, F., Beebe, C., Chen, X. M., Crawford, A., Cuddeback, J., Gabbay, R. A., Kissela, L., Litchman, M. L., Mehta, R., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14455 · Cited by 99 · see citing works
Road Maps to Achieve Glycemic Control in Type 2 Diabetes Mellitus
Jellinger, P. S., Davidson, J. A., Blonde, L., EINHORN, D. F., Grunberger, G., Handelsman, Y., Hellman, R., Lebovitz, H. E., Levy, P., & Roberts, V. L. (2007) · Endocrine Practice · doi:10.4158/ep.13.3.260 · Cited by 92 · see citing works
Self-citation
American Association of Clinical Endocrinology Consensus Statement: Addressing Stigma and Bias in the Diagnosis and Management of Patients with Obesity/Adiposity-Based Chronic Disease and Assessing Bias and Stigmatization as Determinants of Disease Severity
Nadolsky, K., Addison, B., Agarwal, M., Almandoz, J. P., Bird, M. D., DeGeeter Chaplin, M., Garvey, W. T., & Kyle, T. K. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.03.272 · Cited by 86 · see citing works
Immunogenicity, safety, and effectiveness of seasonal influenza vaccination in patients with diabetes mellitus: A systematic review
Dos Santos, G., Tahrat, H., & Bekkat-Berkani, R. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1446719 · Cited by 83 · see citing works
Association of small dense low-density lipoprotein with cardiovascular outcome in patients with coronary artery disease and diabetes: A prospective, observational cohort study
Jin, J.-L., Zhang, H.-W., Cao, Y.-X., Liu, H.-H., Hua, Q., Li, Y.-F., Zhang, Y., Wu, N.-Q., Zhu, C.-G., Xu, R.-X., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01015-6 · Cited by 82 · see citing works
Association of nonfasting vs fasting lipid levels with risk of major coronary events in the Anglo-Scandinavian cardiac outcomes trial-lipid lowering arm
Mora, S., Chang, C. L., Moorthy, M. V., & Sever, P. S. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.0392 · Cited by 70 · see citing works
Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: systematic review and meta-analysis of trials
Khan, S. U., Khan, M. U., Valavoor, S., Khan, M. S., Okunrintemi, V., Mamas, M. A., Leucker, T. M., Blaha, M. J., & Michos, E. D. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487319871733 · Cited by 67 · see citing works
Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus
Young, L. H., Viscoli, C. M., Curtis, J. P., Inzucchi, S. E., Schwartz, G. G., Lovejoy, A. M., Furie, K. L., Gorman, M. J., Conwit, R., Abbott, J. D., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.024863 · Cited by 66 · see citing works
GLP-1 receptor agonists in diabetes for stroke prevention: a systematic review and meta-analysis
Malhotra, K., Katsanos, A. H., Lambadiari, V., Goyal, N., Palaiodimou, L., Kosmidou, M., Krogias, C., Alexandrov, A. V., & Tsivgoulis, G. (2020) · Journal of Neurology · doi:10.1007/s00415-020-09813-4 · Cited by 65 · see citing works
DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases
Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Beckman, J. A., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108101 · Cited by 64 · see citing works
Self-citation
Seven-year mortality in heart failure patients with undiagnosed diabetes: an observational study
Roux, J. A. F., Colet, J. C., Pedro‐Botet, J., Benaiges, D., de Dou, J. P., Chillarón, J. J., Goday, A., Bruguera, J., & Cano-Pérez, J. F. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-39 · Cited by 61 · see citing works
Impact of Novel Low-Density Lipoprotein-Cholesterol Assessment on the Utility of Secondary Non-High-Density Lipoprotein-C and Apolipoprotein B Targets in Selected Worldwide Dyslipidemia Guidelines
Sathiyakumar, V., Park, J., Quispe, R., Elshazly, M. B., Michos, E. D., Banach, M., Toth, P. P., Whelton, S. P., Blumenthal, R. S., Jones, S. R., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032463 · Cited by 58 · see citing works
Two-year-supervised resistance training prevented diabetes incidence in people with prediabetes: A randomised control trial
Dai, X., Zhai, L., Chen, Q., Miller, J. D., Lu, L., Hsue, C., Liu, L., Yuan, X., Wei, W., Ma, X., et al. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3143 · Cited by 56 · see citing works
Age, Gender, and Race‐Based Coronary Artery Calcium Score Percentiles in the Brazilian Longitudinal Study of Adult Health (<scp>ELSA</scp>‐Brasil)
Pereira, A. C., Gomez, L. M., Bittencourt, M. S., Staniak, H. L., Sharovsky, R., Foppa, M., Blaha, M. J., Bensenor, I. M., & Lotufo, P. A. (2016) · Clinical Cardiology · doi:10.1002/clc.22539 · Cited by 55 · see citing works
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2015 Executive Summary
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S. E., Davidson, M., EINHORN, D. F., Garber, J. R., et al. (2015) · Endocrine Practice · doi:10.4158/ep151063.cs · Cited by 55 · see citing works
Self-citation
Durability of triple combination therapy versus stepwise addition therapy in patients with new-onset T2DM: 3-year follow-up of EDICT
Abdul-Ghani, M., Puckett, C., Adams, J., Khattab, A., Baskoy, G., Cersosimo, E., Triplitt, C., & DeFronzo, R. A. (2021) · Diabetes Care · doi:10.2337/dc20-0978 · Cited by 55 · see citing works
Correction to: Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association
(2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atv.0000000000000081 · Cited by 54 · see citing works
Development of a Highly Stable, Nonaqueous Glucagon Formulation for Delivery via Infusion Pump Systems
Newswanger, B., Ammons, S., Phadnis, N. V., Ward, W. K., Castle, J. R., Campbell, R. W., & Prestrelski, S. J. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814565131 · Cited by 51 · see citing works
Safety of liraglutide in type 2 diabetes and chronic kidney disease
Mann, J. F. E., Fonseca, V. A., Poulter, N. R., Raz, I., Idorn, T., Rasmussen, S., von Scholten, B. J., Mosenzon, O., & on behalf of the LEADER Trial Investigators (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11881019 · Cited by 50 · see citing works
Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists
Berra, C., Manfrini, R., Regazzoli, D., Radaelli, M. G., Disoteo, O., Sommese, C., Fiorina, P., Ambrosio, G., & Folli, F. B. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105052 · Cited by 49 · see citing works
The Dietary Approaches to Stop Hypertension (DASH) Clinical Trial Implications for Lifestyle Modifications in the Treatment of Hypertensive Patients
Conlin, P. R. (1999) · Cardiology in Review · doi:10.1097/00045415-199909000-00013 · Cited by 48 · see citing works
Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24‐week, randomized, open‐label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart ( <scp>L</scp> anScape)
Vora, J., Cohen, N., Evans, M., Hockey, A., Speight, J., & Whately‐Smith, C. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12528 · Cited by 44 · see citing works
Intranasal Glucagon
Pontiroli, A. E. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814557518 · Cited by 39 · see citing works
The long-term impact of renin-angiotensin system (RAS) inhibition on cardiorenal outcomes (LIRICO): A randomized, controlled trial
Saglimbene, V., Palmer, S. C., Ruospo, M., Natale, P., Maione, A., Nicolucci, A., Vecchio, M., Tognoni, G., Craig, J. C., Pellegrini, F., et al. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018040443 · Cited by 39 · see citing works
Dietary sugars versus glucose tablets for first-aid treatment of symptomatic hypoglycaemia in awake patients with diabetes: A systematic review and meta-analysis
Carlson, J. N., Schunder-Tatzber, S., Neilson, C. J., & Hood, N. (2017) · Emergency Medicine Journal · doi:10.1136/emermed-2015-205637 · Cited by 32 · see citing works
Adverse differences in cardiometabolic risk factor levels between individuals with pre-diabetes and normal glucose metabolism are more pronounced in women than in men: the Maastricht study
de Ritter, R., Sep, S. J. S., van der Kallen, C. J. H., Schram, M. T., Koster, A., Kroon, A. A., van Greevenbroek, M. M. J., Eussen, S. J. P. M., Dagnelie, P. C., de Jong, M., et al. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000787 · Cited by 32 · see citing works
Predictive value of abnormal ankle-brachial index in patients with diabetes: A meta-analysis
Nie, F., He, J., Cao, H., & Hu, X. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108723 · Cited by 32 · see citing works
Statin-Associated Muscle Symptoms Among New Statin Users Randomly Assigned to Vitamin D or Placebo
Hlatky, M. A., Gonzalez, P. A. E., Manson, J. E., Buring, J. E., Lee, I.-M. M., Cook, N. R., Mora, S., Bubes, V. Y., & Stone, N. J. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.4250 · Cited by 31 · see citing works
Erratum. Reduction in the Incidence of Type 2 Diabetes With the Mediterranean Diet: Results of the PREDIMED-Reus nutrition intervention randomized trial. Diabetes Care 2011;34:14–19
Salas‐Salvadó, J., Bulló, M., Babió, N., Martínez‐González, M. Á., Ibarrola-Jurado, N., Basora, J., Estruch, R., Covas, M. I., Corella, D., Arós, F., et al. (2018) · Diabetes Care · doi:10.2337/dc18-er10 · Cited by 30 · see citing works
Efficacy and safety of different basal and prandial insulin analogues for the treatment of type 2 diabetes: a network meta-analysis of randomized controlled trials
Mannucci, E., Caiulo, C., Naletto, L., Madama, G., & Monami, M. (2021) · Endocrine · doi:10.1007/s12020-021-02889-6 · Cited by 30 · see citing works
Warranty Period of Zero Coronary Artery Calcium Score for Predicting All-Cause Mortality According to Cardiac Risk Burden in Asymptomatic Korean Adults
Lee, J. H., Han, D., Hartaigh, B. Ó., Rizvi, A., Gransar, H., Park, H., Park, H. E., Choi, S., Chun, E. J., Sung, J., et al. (2016) · Circulation Journal · doi:10.1253/circj.cj-16-0731 · Cited by 26 · see citing works
BeAM value: an indicator of the need to initiate and intensify prandial therapy in patients with type 2 diabetes mellitus receiving basal insulin
Zisman, A., Morales, F., Stewart, J. A., Stuhr, A., Vlajnic, A., & Zhou, R. (2016) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2015-000171 · Cited by 23 · see citing works
Comparison of lixisenatide in combination with basal insulin vs other insulin regimens for the treatment of patients with type 2 diabetes inadequately controlled by basal insulin: Systematic review, network meta‐analysis and cost‐effectiveness analysis
Men, P., Qu, S., Luo, W., Li, C., & Zhai, S. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13871 · Cited by 23 · see citing works
Impaired fasting glucose and major adverse cardiovascular events by hypertension and dyslipidemia status: the Golestan cohort study
Hashemi Madani, N., Ismail-Beigi, F., Poustchi, H., Nalini, M., Sepanlou, S. G., Malek, M., Abbasi, M. A., Khajavi, A., Khamseh, M. E., & Malekzadeh, R. (2020) · BMC Cardiovascular Disorders · doi:10.1186/s12872-020-01390-8 · Cited by 22 · see citing works
Comparison of a ready-to-use liquid glucagon injection administered by autoinjector to glucagon emergency kit for the symptomatic relief of severe hypoglycemia: Two randomized crossover non-inferiority studies
Christiansen, M. P., Cummins, M., Prestrelski, S., Close, N. C., Nguyen, A., & Junaidi, K. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002137 · Cited by 22 · see citing works
Prevalence of chronic kidney disease among individuals with diabetes in the SUPREME-DM project, 2005-2011
Schroeder, E. B., Powers, J. D., O’Connor, P. J., Nichols, G. A., Xu, S., Desai, J. R., Karter, A. J., Morales, L. S., Newton, K. M., Pathak, R. D., et al. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.04.007 · Cited by 19 · see citing works
Bias in the measure of the effectiveness of seasonal influenza vaccination among diabetics
Casanova, L., Gobin, N., Villani, P., & Verger, P. (2016) · Primary Care Diabetes · doi:10.1016/j.pcd.2016.05.005 · Cited by 19 · see citing works
Coronary artery calcification under statin therapy and its effect on cardiovascular outcomes: A systematic review and meta-analysis
Lai, R., Ju, J., Lin, Q., & Xu, H. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.600497 · Cited by 19 · see citing works
Corrigendum to: Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
(2022) · European Heart Journal · doi:10.1093/eurheartj/ehab886 · Cited by 18 · see citing works
Untitled work
(2017) · PubMed · Cited by 15 · see citing works
Stroke risk factors in United States: an analysis of the 2013-2018 National Health and Nutrition Examination Survey
Ren, Z., & Fu, X. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s327075 · Cited by 15 · see citing works
Usefulness of glucagon-like peptide-1 receptor agonists to reduce adverse cardiovascular disease events in patients with type 2 diabetes mellitus
Grewal, S., Zaman, N., Borgatta, L., Nudy, M., Foy, A. J., & Peterson, B. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.05.043 · Cited by 14 · see citing works
Traditional cardiovascular disease risk factors associated with one-year all-cause mortality among those with coronary artery calcium scores ≥400
Al Rifai, M., McEvoy, J. W., Nasir, K., Rumberger, J., Feldman, D., Budoff, M. J., & Blaha, M. J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.002 · Cited by 12 · see citing works
Updated risk factors should be used to predict development of diabetes
Bethel, M. A., Hyland, K. A., Chacra, A. R., Deedwania, P., Fulcher, G. R., Holman, R. R., Jenssen, T., Levitt, N. S., McMurray, J. J. V., Boutati, E., et al. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.02.012 · Cited by 12 · see citing works
Relation of Impaired Fasting and Postload Glucose With Incident Type 2 Diabetes in a Dutch Population: The Hoorn Study
de Vegt, F., Dekker, J. M., Jager, A., Hienkens, E., Kostense, P. J., Stehouwer, C. D. A., Nijpels, G., Bouter, L. M., & Heine, R. J. (2001) · JAMA · doi:10.1001/jama.285.16.2109 · Cited by 10 · see citing works
Correction
(2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.11.019 · Cited by 3 · see citing works

Flagged first, then by citations

4 of the 181 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

2008, Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes, N Engl J Med, 358, 2545
Mechanick, 2019, Endocr Pract, 25, 1346

Sorted by citations

American Association of Clinical Endocrinology Consensus Statement: Algorithm for the Evaluation and Treatment of Adults with Obesity/Adiposity-Based Chronic Disease – 2025 Update
Nadolsky, K., Garvey, W. T., Agarwal, M., Bonnecaze, A., Burguera, B., Chaplin, M. D., Griebeler, M. L., Harris, S. R., Schellinger, J. N., Simonetti, J., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.07.017 · Cited by 141 · see citing works
Diagnosis and Treatment of Type 2 Diabetes in Adults
Kalyani, R. R., Neumiller, J. J., Maruthur, N. M., & Wexler, D. J. (2025) · JAMA · doi:10.1001/jama.2025.5956 · Cited by 145 · see citing works
Early onset type 2 diabetes mellitus: an update
Strati, M., Moustaki, M., Ψαλτοπούλου, Θ., Vryonidou, A., & Paschou, S. Α. (2024) · Endocrine · doi:10.1007/s12020-024-03772-w · Cited by 142 · see citing works
Metformin: Therapeutic profile in the treatment of type 2 diabetes
Bailey, C. J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15663 · Cited by 131 · see citing works
A systematic umbrella review and meta-meta-analysis of eHealth and mHealth interventions for improving lifestyle behaviours
Singh, B., Ahmed, M., Staiano, A. E., Gough, C., Petersen, J., Vandelanotte, C., Kracht, C., Huong, C., Yin, Z., Vasiloglou, M. F., et al. (2024) · npj Digital Medicine · doi:10.1038/s41746-024-01172-y · Cited by 115 · see citing works
Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement
Oprea, A. D., Ostapenko, L. J., Sweitzer, B., Selzer, A., Irizarry-Alvarado, J. M., Hurtado Andrade, M. D., Mendez, C. E., Kelley, K. D., Stewart, E., Fernandez Robles, C. R., et al. (2025) · British Journal of Anaesthesia · doi:10.1016/j.bja.2025.04.001 · Cited by 104 · see citing works
Self-citation
Advances in the management of type 2 diabetes in adults
Galindo, R. J., Trujillo, J. M., Wang, C. C. L., & McCoy, R. G. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2022-000372 · Cited by 80 · see citing works
Self-citation
Functional and Clinical Importance of SGLT2-inhibitors in Frailty: From the Kidney to the Heart
Santulli, G., Varzideh, F., Forzano, I., Wilson, S. M., Salemme, L., Donato, A. D., Lombardi, A., Rainone, A., Nunziata, L., Jankauskas, S. S., et al. (2023) · Hypertension · doi:10.1161/hypertensionaha.123.20598 · Cited by 74 · see citing works
Comparing Continuous Glucose Monitoring and Blood Glucose Monitoring in Adults With Inadequately Controlled, Insulin-Treated Type 2 Diabetes (Steno2tech Study): A 12-Month, Single-Center, Randomized Controlled Trial
Lind, N., Christensen, M. B., Hansen, D. L., & Nørgaard, K. (2024) · Diabetes Care · doi:10.2337/dc23-2194 · Cited by 73 · see citing works
Technology and health inequities in diabetes care: How do we widen access to underserved populations and utilize technology to improve outcomes for all
Ebekozien, O., Fantasia, K., Farrokhi, F., Sabharwal, A., & Kerr, D. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15470 · Cited by 70 · see citing works
Advances in Traditional Chinese Medicine research in diabetic kidney disease treatment
Shen, S., Zhong, H., Zhou, X., Li, G., Zhang, C., Zhu, Y., & Yang, Y. M. (2024) · Pharmaceutical Biology · doi:10.1080/13880209.2024.2314705 · Cited by 74 · see citing works
Current barriers to initiating insulin therapy in individuals with type 2 diabetes
Sanz-Pastor, A. G., Enríquez, A. J., Bao, A. S., & Ampudia‐Blasco, F. J. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1366368 · Cited by 66 · see citing works
Combination therapy: an upcoming paradigm to improve kidney and cardiovascular outcomes in chronic kidney disease
Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae212 · Cited by 70 · see citing works
Combination of Cardiovascular, Kidney, and Metabolic Diseases in a Syndrome Named Cardiovascular-Kidney-Metabolic, With New Risk Prediction Equations
Massy, Z. A., & Drüeke, T. B. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.05.033 · Cited by 68 · see citing works
Oral-gut microbial transmission promotes diabetic coronary heart disease
Li, Y., Liu, Y., Cui, J., Zhu, M., Wang, W., Chen, K., Huang, L., & Liu, Y. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02217-y · Cited by 51 · see citing works
Credibility of ChatGPT in the assessment of obesity in type 2 diabetes according to the guidelines
Barlas, T., Altınova, A. E., Aktürk, M., & Törüner, F. B. (2023) · International Journal of Obesity · doi:10.1038/s41366-023-01410-5 · Cited by 50 · see citing works
Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes
Khera, R., Aminorroaya, A., Dhingra, L. S., Thangaraj, P. M., Pedroso Camargos, A., Bu, F., Ding, X., Nishimura, A., Anand, T. V., Arshad, F., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.05.069 · Cited by 47 · see citing works
Type 2 Diabetes
Crawford, A. L., & Laiteerapong, N. (2024) · Annals of Internal Medicine · doi:10.7326/aitc202406180 · Cited by 47 · see citing works
Standards of Specialized Diabetes Care / Edited by Dedov I.I., Shestakova M.V., Sukhareva O.Yu. 12th Edition
Dedov, I., Shestakova, M., Sukhareva, O., Mokrysheva, N., Andreeva, E., Bezlepkina, O., Peterkova, V., Artemova, E., Bardiugov, P., Bessmertnaya, E., et al. (2025) · Diabetes Mellitus · doi:10.14341/dm20255s · Cited by 45 · see citing works
Perioperative Management of Patients Taking Glucagon-like Peptide-1 Receptor Agonists: Applying Evidence to Clinical Practice
Oprea, A. D., Umpierrez, G. E., Sweitzer, B., & Hepner, D. L. (2024) · Anesthesiology · doi:10.1097/aln.0000000000005204 · Cited by 40 · see citing works
Self-citation
MetALD: Clinical aspects, pathophysiology and treatment
Gratacós‐Ginès, J., Ariño, S., Sancho‐Bru, P., Bataller, R. A., & Pose, E. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101250 · Cited by 42 · see citing works
Chinese expert consensus on blood lipid management in patients with diabetes (2024 edition)
Xiao, Y., Yu, B., Chen, C., Wang, S., Hu, D., Wu, C., Luo, Y., Xie, L., Li, C., Peng, D., et al. (2024) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2024-0014 · Cited by 36 · see citing works
Trajectory of the body weight after drug discontinuation in the treatment of anti-obesity medications
Wu, H., Yang, W., Guo, T., Cai, X., & Ji, L. (2025) · BMC Medicine · doi:10.1186/s12916-025-04200-0 · Cited by 36 · see citing works
SGLT2 inhibitor use in the management of feline diabetes mellitus
Cook, A. K., & Behrend, E. N. (2024) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.13466 · Cited by 33 · see citing works
Current type 2 diabetes guidelines: Individualized treatment and how to make the most of metformin
Chan, J. C. N., Yang, A., Chu, N. H. S., & Chow, E. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15700 · Cited by 35 · see citing works
Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2025) · Peptides · doi:10.1016/j.peptides.2025.171380 · Cited by 34 · see citing works
SGLT2 inhibitors across various patient populations in the era of precision medicine: the multidisciplinary team approach
McLean, P., Bennett, J., Woods, E. A., Chandrasekhar, S. A., Newman, N. A., Mohammad, Y., Khawaja, M., Rizwan, A. M., Siddiqui, R., Birnbaum, Y., et al. (2025) · npj Metabolic Health and Disease · doi:10.1038/s44324-025-00068-z · Cited by 34 · see citing works
Self-citation
SGLT2 inhibitors: an evidence-based update on cardiovascular implications
Forzano, I., Wilson, S. M., Lombardi, A., Jankauskas, S. S., Kansakar, U., Mone, P., Varzideh, F., & Santulli, G. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2263354 · Cited by 32 · see citing works
Real-Time AI-Assisted Insulin Titration System for Glucose Control in Patients With Type 2 Diabetes
Ying, Z., Fan, Y., Chen, C., Liu, Y., Tang, Q., Chen, Z., Yang, Q., Yan, H., Wu, L., Lu, J., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.8910 · Cited by 30 · see citing works
Reframing prediabetes: A call for better risk stratification and intervention
Kim, S. H. (2024) · Journal of Internal Medicine · doi:10.1111/joim.13786 · Cited by 30 · see citing works
Renoprotective mechanisms of glucagon-like peptide-1 receptor agonists
Chen, J., Cooper, M., & Coughlan, M. T. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101641 · Cited by 30 · see citing works
Efficacy, adherence and persistence of various glucagon‐like peptide‐1 agonists: nationwide real‐life data
Kassem, S., Khalaila, B., Stein, N., Saliba, W., & Zaina, A. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15828 · Cited by 28 · see citing works
Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system
McCall, K. L., Mastro, K. A., Casey, R. T., Samana, T. N., Sulicz, E. K., Tso, S. Y., Yalanzhi, E. R., & Piper, B. J. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2499670 · Cited by 28 · see citing works
Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review
Kunutsor, S. K., & Seidu, S. (2025) · Drugs · doi:10.1007/s40265-025-02263-0 · Cited by 32 · see citing works
Initial Combination Therapy in Type 2 Diabetes
Kim, J. Y., & Kim, N. H. (2023) · Endocrinology and Metabolism · doi:10.3803/enm.2023.1816 · Cited by 33 · see citing works
Lifestyle Interventions for Treatment and Remission of Type 2 Diabetes and Prediabetes in Adults: A Clinical Practice Guideline From the American College of Lifestyle Medicine
Rosenfeld, R. M., Grega, M. L., Karlsen, M. C., Dabrh, A. M. A., Aurora, R. N., Bonnet, J. P., Donnell, L., Fitzpatrick, S. L., Frates, E. P., Joy, E. A., et al. (2025) · American Journal of Lifestyle Medicine · doi:10.1177/15598276251325488 · Cited by 31 · see citing works
Self-citation
Real-world Evidence on Oral Semaglutide for the Management of Type 2 Diabetes. A Narrative Review for Clinical Practice
Marassi, M., & Fadini, G. P. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.11.005 · Cited by 25 · see citing works
Effectiveness and safety of combining SGLT2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of cohort studies
Colombijn, J. M. T., de Leijer, J. F., Visseren, F. L. J., Verhaar, M. C., van Raalte, D. H., Sattar, N. A., Vernooij, R. W. M., & van Sloten, T. T. (2025) · Diabetologia · doi:10.1007/s00125-025-06565-6 · Cited by 24 · see citing works
Real-life underuse of SGLT2 inhibitors for patients with type 2 diabetes at high cardiorenal risk
Scheen, A. J. (2023) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2023.100184 · Cited by 24 · see citing works
Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide
Billings, L. K., Winne, L., Sharma, P., Valderas, E. G., Chivukula, K. K., & Kwan, A. Y. M. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-03849 · Cited by 25 · see citing works
Sodium-Glucose Cotransporter-2 Inhibitors in Diabetes and Beyond: Mechanisms, Pleiotropic Benefits, and Clinical Use—Reviewing Protective Effects Exceeding Glycemic Control
Hanke, J., Romejko, K., & Niemczyk, S. (2025) · Molecules · doi:10.3390/molecules30204125 · Cited by 27 · see citing works
American Association of Clinical Endocrinology Consensus Statement: Algorithm for Management of Adults With Type 2 Diabetes – 2026 Update
Samson, S. L., Vellanki, P., Blonde, L., Hirsch, I. B., Hoang, T. D., Isaacs, S. D., Izuora, K. E., Wang, C. C. L., Ooi, C. P., Padilla, B. I., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.006 · Cited by 27 · see citing works
Self-citation
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium–Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure
Gallo, G., & Volpe, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052484 · Cited by 23 · see citing works
Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiac Function, Exercise Capacity and Quality of Life
Shchendrygina, A., Rakisheva, A., Giverts, I., Rustamova, Y., & Soloveva, A. E. (2024) · Cardiac failure review · doi:10.15420/cfr.2024.05 · Cited by 21 · see citing works
Switching to Tirzepatide 5 mg From Glucagon-Like Peptide-1 Receptor Agonists: Clinical Expectations in the First 12 Weeks of Treatment
Jabbour, S. A., Paik, J. S., Aleppo, G., Sharma, P., Valderas, E. G., & Benneyworth, B. D. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.05.005 · Cited by 22 · see citing works
Circadian rhythm disruption and endocrine-related tumors
Savvidis, C., Kallistrou, E., Kouroglou, E., Dionysopoulou, S., Gavriiloglou, G., Ragia, D., Tsiama, V., Proikaki, S., Belis, K., & Ilias, Ι. (2024) · World Journal of Clinical Oncology · doi:10.5306/wjco.v15.i7.818 · Cited by 23 · see citing works
Perioperative Management of Adult Patients with Diabetes Wearing Devices: A Society for Perioperative Assessment and Quality Improvement (SPAQI) Expert Consensus Statement
Oprea, A. D., Kalra, S. K., Duggan, E. W., Russell, L., Urman, R. D., Abdelmalak, B., Patel, P., Pfeifer, K. J., Grant, P., Charitou, M. M., et al. (2024) · Journal of Clinical Anesthesia · doi:10.1016/j.jclinane.2024.111627 · Cited by 20 · see citing works
Self-citation
Transforming steatotic liver disease management: The emerging role of GLP-1 receptor agonists
Jensen, E., Israelsen, M. E., & Krag, A. A. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000561 · Cited by 23 · see citing works
Glucagonlike Peptide-1 Receptor Agonists: The Good, the Bad, and the Ugly—Benefits for Glucose Control and Weight Loss with Side Effects of Delaying Gastric Emptying
Parkman, H. P., Rim, D. S., Anolik, J. R., Dadparvar, S., & Maurer, A. H. (2024) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.123.266800 · Cited by 20 · see citing works
Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group Technique
Yepes, C. A., Cardenas-Moreno, I. C., Daza-Arnedo, R., Fériz, K., Yama-Mosquera, E., Rincón, A. R., Castillo, G. A., Suarez-Rodriguez, A. F., Carreño-Jiménez, J., & Builes-Montaño, C. E. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01722-x · Cited by 19 · see citing works
Real‐world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus
Kelly, M. S., Scopelliti, E. M., Goodson, K. E., Lo, C. M. A., Nguyen, H. X., & Simon, B. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15934 · Cited by 21 · see citing works
Diabetes and cardiovascular disease in older adults
Bilal, A., & Pratley, R. E. (2024) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15259 · Cited by 18 · see citing works
Canagliflozin may increase thromboembolic events in males with erythrocytosis but not in females
Doi, Y., Hamano, T., Yamaguchi, O., & Isaka, Y. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016320 · Cited by 18 · see citing works
Efficacy and Safety of Pioglitazone Add-on in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin and Dapagliflozin: A Multicenter, Randomized, Double-blind, and Placebo-controlled Study
Cho, Y. K., Kim, K. S., Lee, B., Hong, J. H., Yu, J. M., Lim, S. K., Kim, Y. A., Lee, C. B., Kim, S. S., Kwak, S. H., et al. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.06.023 · Cited by 18 · see citing works
Continuous glucose monitoring for self-management of diabetes in people living with type 2 diabetes mellitus on basal insulin therapy: A microsimulation model and cost-effectiveness analysis from a US perspective with relevance to Medicaid
Frank, J., Son, D., Szafranski, K., & Poon, Y. (2024) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2024.24025 · Cited by 18 · see citing works
Prediabetes and Cardiometabolic Risk: The Need for Improved Diagnostic Strategies and Treatment to Prevent Diabetes and Cardiovascular Disease
Lizarzaburu-Robles, J. C., Herman, W. H., Garro-Mendiola, A., Sanz-Pastor, A. G., & Lorenzo, Ó. (2024) · Biomedicines · doi:10.3390/biomedicines12020363 · Cited by 17 · see citing works
Key results from observational studies and real‐world evidence of sodium‐glucose cotransporter‐2 inhibitor effectiveness and safety in reducing cardio‐renal risk
Nyström, T. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15696 · Cited by 17 · see citing works
Effectiveness of Digital Diabetes Management Technology on Blood Glucose in Patients With Type 2 Diabetes at Home: Systematic Review and Meta-Analysis
Xiao, Y., Wang, Z., Zhang, L., Xie, N., Chen, F., Song, Z., & Zhao, S. (2025) · Journal of Medical Internet Research · doi:10.2196/66441 · Cited by 21 · see citing works
Optimization of guideline-directed medical therapies in patients with diabetes and chronic kidney disease
Neumiller, J. J., Alicic, R. Z., & Tuttle, K. R. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad285 · Cited by 16 · see citing works
Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile
Scheen, A. J. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2354885 · Cited by 17 · see citing works
Pharmacological therapies for type 2 diabetes: future approaches
Bailey, C. J. (2025) · Diabetologia · doi:10.1007/s00125-025-06581-6 · Cited by 19 · see citing works
Large Language Model GPT-4 Compared to Endocrinologist Responses on Initial Choice of Glucose-Lowering Medication Under Conditions of Clinical Uncertainty
Flory, J., Ancker, J. S., Kim, S. Y. H., Kuperman, G. J., Petrov, A., & Vickers, A. J. (2024) · Diabetes Care · doi:10.2337/dc24-1067 · Cited by 18 · see citing works
Role of anti-diabetic medications in the management of MASLD
Isaacs, S. D., Farrelly, F. V., & Brennan, P. (2025) · Frontline Gastroenterology · doi:10.1136/flgastro-2024-102856 · Cited by 17 · see citing works
Self-citation
Distinct Roles of Common Genetic Variants and Their Contributions to Diabetes: MODY and Uncontrolled T2DM
Bazzazzadehgan, S., Shariat‐Madar, Z., & Mahdi, F. (2025) · Biomolecules · doi:10.3390/biom15030414 · Cited by 18 · see citing works
Glycemic Targets and Prevention of Complications
Tsushima, Y., & Galloway, N. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae776 · Cited by 15 · see citing works
Dietary Advanced Glycation End Products and Cardiovascular-Kidney-Metabolic Complications
Uribarri, J., & Tuttle, K. R. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000859 · Cited by 15 · see citing works
Are we ready for an adipocentric approach in people living with type 2 diabetes and chronic kidney disease?
Moreno, Ó., Reyes‐García, R., Pardo, I. M., López-Martínez, M., & Soler, M. J. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae039 · Cited by 14 · see citing works
Tirzepatide for type 2 diabetes
Anderson, S. L., & Marrs, J. C. (2023) · Drugs in Context · doi:10.7573/dic.2023-6-1 · Cited by 13 · see citing works
Diabetes Technology in People with Type 2 Diabetes: Novel Indications
Agarwal, S., Galindo, R. J., Shah, A. V., & Abreu, M. (2024) · Current Diabetes Reports · doi:10.1007/s11892-024-01536-4 · Cited by 12 · see citing works
Self-citation
Narrative review of data supporting alternate first-line therapies over metformin in type 2 diabetes
Andraos, J., Smith, S. R., Tran, A., & Pham, D. Q. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01406-6 · Cited by 13 · see citing works
Antidiabetic Treatment and Prevention of Ischemic Stroke: A Systematic Review
Prentza, V., Pavlidis, G., Ikonomidis, I., Pililis, S., Lampsas, S., Kountouri, A., Pliouta, L., Korakas, E., Thymis, J., Palaiodimou, L., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13195786 · Cited by 13 · see citing works
Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Receptor Agonists: A Scoping Review
Ceron, E. L., Reddy, S. D., Kattamuri, L. P. V., Muvva, D. M., Chozet, L. E., & Bright, T. M. (2025) · Journal of Brown Hospital Medicine · doi:10.56305/001c.132255 · Cited by 12 · see citing works
Comparative safety and cardiovascular effectiveness of sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists in nursing homes
Riester, M. R., Zullo, A. R., Joshi, R., Daiello, L. A., Hayes, K. N., Ko, D., Kim, D. H., Munshi, M. N., & Berry, S. D. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15682 · Cited by 12 · see citing works
Multireceptor Analysis for Evaluating the Antidiabetic Efficacy of Karanjin: A Computational Approach
Nag, S., Stany, B. K., Mishra, S., Kumar, S., Mohanto, S., Ahmed, M. G., Mathew, B., & Subramaniyan, V. (2024) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.509 · Cited by 12 · see citing works
Pulmonary outcomes of incretin-based therapies in COPD patients receiving single-inhaler triple therapy
See, X. Y., Xanthavanij, N., Lee, Y.-C., Ong, T. E., Wang, T. H., Ahmed, O., Chang, Y., Peng, C.-Y., Chi, K.-Y., Chang, Y., et al. (2024) · ERJ Open Research · doi:10.1183/23120541.00803-2024 · Cited by 12 · see citing works
Metformin-mediated protection against doxorubicin-induced cardiotoxicity
Sun, M., Dong, J.-M., Liu, C., Li, P., Zhang, C., Zhen, J., & Chen, W. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117535 · Cited by 12 · see citing works
Adipocentric Strategy for the Treatment of Type 2 Diabetes Mellitus
Martínez, J. J. G. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14030678 · Cited by 12 · see citing works
Large Language Models in Diabetes Management: The Need for Human and Artificial Intelligence Collaboration
Pavon, J. M., Schlientz, D., Maciejewski, M. L., Economou-Zavlanos, N., & Lee, R. (2025) · Diabetes Care · doi:10.2337/dci24-0079 · Cited by 12 · see citing works
Effect of Moringa oleifera Leaf Extract on Glycemic Parameters in Patients with Type 2 Diabetes Mellitus and Prediabetes: A Systematic Review and Meta-analysis
Kamrul-Hasan, A. B. M., Talukder, S. K., Nagendra, L., Alam, M. S., Aalpona, F. T. Z., Dutta, D., & Selim, S. (2023) · Bangladesh Journal of Endocrinology and Metabolism · doi:10.4103/bjem.bjem_26_23 · Cited by 12 · see citing works
Efficacy and safety of tirzepatide in people with type 2 diabetes by baseline body mass index: An exploratory subgroup analysis of SURPASS-AP-Combo
Ma, J., Liu, M., Wang, R., Du, L., & Ji, L. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15446 · Cited by 12 · see citing works
A narrative review of glucagon-like peptide-1 receptor agonists prior to deep sedation or general anesthesia
Vetrugno, L., Deana, C., Porto, A. D., Boero, E., Bellini, V., Biasucci, D. G., & Bignami, E. G. (2025) · Journal of Anesthesia Analgesia and Critical Care · doi:10.1186/s44158-025-00237-y · Cited by 12 · see citing works
Updates from the 2025 American Diabetes Association guidelines on standards of medical care in diabetes
Tiwari, D., Loh, W. J., & Aw, T. C. (2025) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2025.101428 · Cited by 11 · see citing works
Metformin-Based Combination Approaches for Triple-Negative Breast Cancer
Sirhan, Z., Nada, A. A., Anabtawi, N., Thyagarajan‐Sahu, A., & Sahu, R. P. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17050558 · Cited by 11 · see citing works
Efficacy and Safety of Pioglitazone Add‐On in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials
Khan, U., Majeed, Z., Khan, M. H., Elsnhory, A. B., Amin, A. M., Nawaz, A., Raza, A., Siddque, H. M. W., Turkmani, M. M., & Abuelazm, M. T. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70061 · Cited by 11 · see citing works
Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?
Scheen, A. J. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2279193 · Cited by 11 · see citing works
Associations between long-term metformin use, the risk of vitamin B12 deficiency, and neuropathy: An All of Us research Program study
Sepassi, A., Wang, J., Yankowski, S., Enkoji, A., Okenwa, M., Morello, C. M., & Hurley‐Kim, K. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112424 · Cited by 11 · see citing works
Tirzepatide in Hispanic/Latino Patients With Type 2 Diabetes: A Subgroup Analysis of the SURPASS Program
Frías, J. P., Galindo, R. J., Wang, H., Malik, R., Chivukula, K. K., & Maldonado, J. M. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad495 · Cited by 10 · see citing works
Self-citation
Development of Long-Acting Dipeptidyl Peptidase-4 Inhibitors: Structural Evolution and Long-Acting Determinants
Li, Q., Deng, X., Xu, Y., & Dong, L. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00412 · Cited by 10 · see citing works
Safety and Effectiveness of Concomitant iGlarLixi and SGLT-2i Use in People with T2D During Ramadan Fasting: A SoliRam Study Sub-analysis
Hassanein, M. M., Malek, R., Sifri, S. A., Sahay, R. K., Büyükbeşe, M. A., Djaballah, K., Melas‐Melt, L., & Shaltout, I. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01642-2 · Cited by 10 · see citing works
Kidney Outcomes with Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas in Type 2 Diabetes and Moderate Cardiovascular Risk
Neumiller, J. J., Herrin, J. S., SWARNA, K. S., Polley, E. C., Galindo, R. J., Umpierrez, G. E., Deng, Y., Ross, J. S., Mickelson, M. M., & McCoy, R. G. (2024) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000587 · Cited by 10 · see citing works
Self-citation
Postprandial Glucose: A Variable in Continuum
Joshi, S., Kesavadev, J., M., P. K. K., Saboo, B., Mehta, A., Bhattacharyya, A., Sosale, A., Jabbar, P. K., Santosh, R., Deshmukh, V. C., et al. (2025) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514251370507 · Cited by 10 · see citing works
Incretin Therapies for Patients with Type 2 Diabetes and Chronic Kidney Disease
Alicic, R. Z., & Neumiller, J. J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010201 · Cited by 13 · see citing works
Expert Opinion on Optimising Type 2 Diabetes Treatment Using Fixed-Ratio Combination of Basal Insulin and GLP-1 RA for Treatment Intensification and Simplification
Haluzı́k, M., Taybani, Z. J., Araszkiewicz, A., Cerghizan, A., Mankovsky, B., Zuhdi, A., & Malecki, M. T. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01610-w · Cited by 10 · see citing works
Stroke in the Patient With Type 2 Diabetes
Jerkins, T. W., & Bell, D. S. H. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.01.010 · Cited by 9 · see citing works
FRONTIER : FReeStyle Libre system use in Ontario among people with diabetes in the IC / ES database—Evidence from real‐world practice: Patients on basal insulin, glucagon‐like peptide 1 receptor agonist or oral therapies
Ratzki‐Leewing, A. A., Harris, S. B., RABASA-LHORET, R. P. R., & Poon, Y. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16266 · Cited by 9 · see citing works
GLP-1 Receptor Analogs: Evidence Linking to Effect on Metabolic and Reproductive Functions in Patients with PCOS and Obesity
Çelik, Ö., Yazıcı, D., Ciudin, A., Macut, D., Micić, D., Yumuk, V., & Yıldız, B. O. (2025) · Obesity Facts · doi:10.1159/000547055 · Cited by 9 · see citing works
Suppressed thyroid stimulating hormone levels after initiation of a subcutaneous glucagon-like peptide-1 receptor agonist in a post-thyroidectomy patient managed with levothyroxine case report
Wilcox, L., & Dril, E. V. (2024) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2024.102185 · Cited by 9 · see citing works
Trends and regional differences in antidiabetic medication use: a nationwide retrospective observational study
Csatordai, M., Benkő, R., Matúz, M., Engi, Z., Csupor, D., Lengyel, C., & Doró, P. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01334-8 · Cited by 8 · see citing works
Advances and counterpoints in type 2 diabetes. What is ready for translation into real-world practice, ahead of the guidelines
Schwartz, S. S., Corkey, B. E., Gavin, J. R., DeFronzo, R. A., & Herman, M. E. (2024) · BMC Medicine · doi:10.1186/s12916-024-03518-5 · Cited by 8 · see citing works
The association between blood glucose levels and lipids in the general adult population: results from NHANES (2005–2016)
Yang, C., Liu, Z., Zhang, L., & Gao, J. (2024) · Journal of Health Population and Nutrition · doi:10.1186/s41043-024-00660-x · Cited by 8 · see citing works

American Association of Clinical Endocrinology Consensus Statement: Algorithm for Management of Adults With Type 2 Diabetes – 2026 Update
Samson, S. L., Vellanki, P., Blonde, L., Hirsch, I. B., Hoang, T. D., Isaacs, S. D., Izuora, K. E., Wang, C. C. L., Ooi, C. P., Padilla, B. I., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.006 · Cited by 27 · see citing works
Self-citation
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2015 Executive Summary
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S. E., Davidson, M., EINHORN, D. F., Garber, J. R., et al. (2015) · Endocrine Practice · doi:10.4158/ep151063.cs · Cited by 55 · see citing works
Self-citation
American Association of Clinical Endocrinologists’ Comprehensive Diabetes Management Algorithm 2013 Consensus Statement
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S. E., Davidson, M., EINHORN, D. F., Garvey, W. T., et al. (2013) · Endocrine Practice · doi:10.4158/ep13176.csuppl · Cited by 219 · see citing works
Self-citation
Comprehensive algorithm released on management of type 2 diabetes
Tanzi, M. G. (2017) · Pharmacy Today · doi:10.1016/j.ptdy.2017.09.028
for the Initiation and Adjustment of Therapy A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
Nathan, D. M., Buse, J. B., Davidson, M. B., Holman, R. R., & Zinman, B. (2013)

Authors: Samson, S. L., Vellanki, P., Blonde, L., Christofides, E. A., Galindo, R. J., Hirsch, I. B., Isaacs, S. D., Izuora, K. E., Low Wang, C. C., Twining, C. L., Umpierrez, G. E., & Valencia, W. M.
Affiliations: Mayo Clinic (US)
Grady Memorial Hospital (US)
Ochsner Health System (US)
Indiana University Columbus (US)
University of Miami (US)
University of Washington (US)
Emory University (US)
University of Nevada, Las Vegas (US)
Maine Medical Center (US)
Cleveland Clinic (US)
ORCID: Samson, Susan L.
Vellanki, Priyathama
Blonde, Lawrence
Christofides, Elena A.
Galindo, Rodolfo J.
Hirsch, Irl B.
Isaacs, Scott D.
Izuora, Kenneth E.
Umpierrez, Guillermo E.
Valencia, Willy Marcos
Venue: Endocrine Practice
Publisher: Elsevier BV
Published: 2023-05
Volume: 29
Issue: 5
Pages: 305-340
ISSN: 1530-891X (ISSN-L)
DOI: 10.1016/j.eprac.2023.02.001
OpenAlex: W4372214811
Semantic Scholar: 066a5bccabf1b093084ed77c43509daa1c94c321
Cited by: 375
References: 181
Citations by year: 2026: 62 · 2025: 150 · 2024: 124 · 2023: 38 · 2022: 1
FWCI: 76.07
Type: journal article
Language: en
Update notices: erratum (2023-12-01)
erratum (2023-09-01)
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Endocrine Practice (publishedVersion)
PubMed (publishedVersion)
Funders: National Institute of Diabetes and Digestive and Kidney Diseases (K23DK123384)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: type 2 diabetes, prediabetes, glycemic control, dyslipidemia, hypertension, insulin intensification, antihyperglycemic medications, anti-obesity drugs, obesity, lifestyle modification, health equity
MeSH terms: Endocrinologists, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Endocrinology, Glucose, Humans, Hypertension, Obesity, Prediabetic State, United States, Dyslipidemias, Overweight

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm—2023 update

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks